Home/Healthcare/Biotechnology/Global Biosimilars Market

Global Biosimilars Market - Strategic Insights and Forecasts (2026-2031)

Biosimilar market insights exploring monoclonal antibodies, insulin biosimilars, and increasing adoption across oncology and autoimmune treatments.

$3,950
Single User License

Report Overview

The Biosimilars Market is forecast to grow at a CAGR of 16.0%, reaching USD 59.0 billion in 2031 from USD 28.1 billion in 2026.

Market Growth Projection (CAGR: 16%)
$28.10B
2026
$32.59B
2027
$59.00B
2031
Global Biosimilars Market - Highlights
Insightful Analysis
Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape
Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends
Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations
Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience
Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

Biosimilars are defined as licensed and highly similar versions of biological drugs that have already been approved for use by regulatory bodies. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics, coupled with the patent expiration of many blockbuster biologic drugs. The estimated patent and exclusivity expiry of a few of the blockbuster biologics is given below. Due to the structural complexity of biosimilar drugs, multi-layered manufacturing, and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market.

Biosimilars Market Growth Drivers:

  • The market is propelled by increasing corporate investments in biosimilar development.

Biosimilars Market Regional Insights:

Europe dominates the global biosimilars market, driven by the presence of leading biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, and Merck. A well-established regulatory framework for biosimilar approvals, a growing number of product approvals, and advanced healthcare infrastructure further fuel market growth in Europe. North America is also expected to experience significant growth during the forecast period, supported by heightened focus on product development and manufacturers' efforts to capitalize on regional growth opportunities.

Market intelligence is delivered through detailed analysis, charts, and graphics, enabling clients to quickly and effectively understand the global biosimilars market.

The Biosimilars Market Report offers a comprehensive analysis of the industry, providing strategic and executive-level insights backed by data-driven forecasts. This regularly updated report empowers decision-makers with actionable intelligence on market trends, emerging opportunities, and competitive dynamics. Biosimilars are defined as biologic products highly similar to licensed biologic drugs, with minor differences in inactive components. The report also examines technological advancements, key government policies, regulatory frameworks, and macroeconomic factors, delivering a holistic market perspective.

Some of the major players covered in this report include Samsung Bioepis, Stada Arzneimittel AG, Sandoz International GmbH (Novartis), Amgen Inc., Apotex Inc., BioCad, Dr. Reddy's Laboratories Ltd., Biocon, Boehringer Ingelheim International GmbH, Pfizer, BioFactura, and AmerisourceBergen Corporation among others.

Key Benefits of this Report:

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030

  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis

  • Competitive Positioning, Strategies, and Market Share Analysis

  • Revenue Growth and Forecast Assessment of segments and regions including countries

  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Biosimilars Market Scope:

Report Metric Details
Total Market Size in 2026 USD 28.1 billion
Total Market Size in 2031 USD 59.0 billion
Forecast Unit Billion
Growth Rate 16.0%
Study Period 2021 to 2031
Historical Data 2021 to 2024
Base Year 2025
Forecast Period 2026 – 2031
Segmentation Type, Disease, Regions
Geographical Segmentation North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies
  • Samsung Bioepis
  • Stada Arzneimittel AG
  • Sandoz International GmbH (Novartis)
  • Amgen Inc.
  • Apotex Inc.
  • BioCad
  • Dr. Reddy's Laboratories Ltd.
  • Biocon
  • Boehringer Ingelheim International GmbH
  • Pfizer

Market Segmentation

By Type

Monoclonal Antibodies
Erythropoietins (EPO)
Granulocyte-Colony Stimulating Factors (G-CSF)
Interferons
Hormone-based Biosimilars
Others

By Disease

Infectious Disease
Oncology and Immunology
Respiratory
Genetic Disorders
Others

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Taiwan
Thailand
Others

Table of Contents

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

4.1. Product Pipeline

4.2. Patent Analysis

5. BIOSIMILARS MARKET BY TYPE

5.1. Introduction

5.2. Monoclonal Antibodies

5.3. Erythropoietins (EPO)

5.4. Granulocyte-Colony Stimulating Factors (G-CSF)

5.5. Interferons

5.6. Hormone-based Biosimilars

5.7. Others

6. BIOSIMILARS MARKET BY DISEASE

6.1. Introduction

6.2. Infectious Disease

6.3. Oncology and Immunology

6.4. Respiratory

6.5. Genetic Disorders

6.6. Others

7. BIOSIMILARS MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. USA

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. France

7.4.4. Italy

7.4.5. Spain

7.4.6. Others

7.5. Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. UAE

7.5.3. Others

7.6. Asia Pacific

7.6.1. China

7.6.2. Japan

7.6.3. India

7.6.4. South Korea

7.6.5. Taiwan

7.6.6. Thailand

7.6.7. Indosneisa

7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Samsung Bioepis

9.2. Stada Arzneimittel AG

9.3. Sandoz International GmbH (Novartis)

9.4. Amgen Inc.

9.5. Apotex Inc.

9.6. BioCad

9.7. Dr. Reddy’s Laboratories Ltd.

9.8. Biocon

9.9. Boehringer Ingelheim International GmbH

9.10. Pfizer

9.11. BioFactura

10. APPENDIX

10.1. Currency 

10.2. Assumptions

10.3. Base and Forecast Years Timeline

10.4. Key Benefits for the Stakeholders

10.5. Research Methodology 

10.6. Abbreviations

Request Customization

Tell us your specific requirements and we will customize this report for you.

πŸ“ž

Your data is secure. We do not share information with any third party.

Download Free Sample

Get a sample copy of this report with charts, TOC, and methodology.

πŸ“ž

Your data is secure. We do not share information with any third party.

Speak to Analyst

Ask our analysts any questions you have about this market research report.

πŸ“ž

Your data is secure. We do not share information with any third party.

Global Biosimilars Market Report

Report IDKSI061611550
PublishedFeb 2026
Pages152
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

The biosimilars market is expected to reach a total market size of USD 59.0 billion by 2031.

Biosimilars Market is valued at USD 28.1 billion in 2026.

The biosimilars market is expected to grow at a CAGR of 16.0% during the forecast period.

The biosimilar market growth may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics coupled with the patent expiration of the many blockbuster biologic drugs.

Geographically, Europe holds the largest share of the biosimilar market due to the presence of well-known biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, Merck, etc.

Need data specifically for your business?Request Custom Research β†’

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon